anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
###  Teratogenic Effects

Prednisolone has been shown to be teratogenic in rabbits, hamsters, and mice. In mice, prednisolone has been shown to be teratogenic when given in doses 1 to 10 times the human ocular dose. Dexamethasone, hydrocortisone and prednisolone were ocularly applied to both eyes of pregnant mice five times per day on days 10 through 13 of gestation. A significant increase in the incidence of cleft palate was observed in the fetuses of the treated mice. There are no adequate, well-controlled studies in pregnant women dosed with corticosteroids.

Kernicterus may be precipitated in infants by sulfonamides given systemically during the third trimester of pregnancy. It is not known whether sulfacetamide sodium can cause fetal harm when administered to a pregnant woman or whether it can affect reproductive capacity.

Sulfacetamide Sodium and Prednisolone Sodium Phosphate Ophthalmic Solution should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.
Placebo contained 0.01 mol/L potassium phosphate buffer containing 0.85% sodium chloride (pH 7.2). Subjects received about 0.1 mL (a total 0.2 mL) of the control drug using a nebulizer.
BACKGROUND: The aim of this study was to analyze short-term outcomes focusing on readmissions after laparoscopic bariatric metabolic surgery (BMS) in an Italian academic Bariatric Center of Excellence IFSO-European Chapter (EC).
METHODS: This is a retrospective study based on the analysis of a prospectively maintained institutional database. Patients aged between 18 and 65 years who underwent primary BMS and/or revisional BMS (RBMS) between 2012 and 2021 were included. Primary endpoint was to analyze the readmission rate at 30 postoperative days. The secondary endpoint involved assessing the causes of readmission within 30 days of discharge, the rates, and types of reoperations and/or additional procedures related to the first surgery, and the outcomes of readmitted patients.
RESULTS: A total of 2297 patients were included in the study. Among them, 2143 underwent primary surgery and 154 patients underwent RBMS. Eighty-two percent of the Enhanced Recovery after Surgery (ERAS) protocol items were applied starting from 2016. Within 30 days after discharge, 48 patients (2.09%) were readmitted. Overall readmission rate following primary and revisional BMS was 2.15%, respectively 1.30%. Ten readmitted patients (20.8%) had complications graded IIIb or more (Clavien-Dindo classification) and needed additional procedures. Mortality rate was 4.17% among readmitted patients.
CONCLUSIONS: Only 2.09% of patients undergoing laparoscopic bariatric surgery were readmitted. Of these, 20.8% required additional procedures. Standardization of surgical techniques and perioperative protocols in a bariatric center of excellence resulted in a low readmission rate even in RBMS.
The invention discloses Bergenia purpurascens(Hook.f.et Thoms.)Engl. extract, a cosmetic additive applying the Bergenia purpurascens(Hook.f.et Thoms.)Engl. extract for realizing skin whitening, moisturizing and antioxidant activity and a combined application of the Bergenia purpurascens(Hook.f.et Thoms.)Engl. extract in cosmetics. The Bergenia purpurascens(Hook.f.et Thoms.)Engl. extract is ethanol extract of Bergenia purpurascens(Hook.f.et Thoms.)Engl. rhizomes and has good DPPH (2,2-diphenyl-1-picrylhydrazyl) free radical scavenging capacity and good tyrosinase activity inhibition effect. The Bergenia purpurascens(Hook.f.et Thoms.)Engl. extract has good antioxidant capacity and melanin removal capacity in the aspect of skin care, that is, the Bergenia purpurascens(Hook.f.et Thoms.)Engl. extract has good skin cosmetic activity application potential in aspects of anti-wrinkle, sunscreen, whitening, melanin (spot) removal. With effective use of Bergenia purpurascens(Hook.f.et Thoms.)Engl. which is the Naxi traditional medicinal plant, the Bergenia purpurascens(Hook.f.et Thoms.)Engl. extract with very high biological activity is obtained, can be used for preparing good antioxidant and tyrosinase activity inhibitor and is a good raw material for herbal cosmetics.
Male subjects will be assigned to one of four cohorts (9, 10, 11 or 12). In each cohort, two subjects will be randomized to receive placebo.
The diagnosis of chronic gastro-intestinal ischemia (CGI) remains a clinical challenge because this diagnosis is difficult to distinguish by the frequent incidence of chronic abdominal pain and asymptomatic stenosis of the mesenteric arteries1. The standard diagnostic work up includes medical history, anamnesis and physical examination, radiological imaging and a functional test as visible light spectroscopy (VLS)2-4 or tonometry5-7. A multidisciplinary team consisting of a gastroenterologist, a vascular surgeon and an interventional radiologist, all specialized in CGI, discusses all patients which results in an expert based consensus diagnosis. Currently, there is no specific test to diagnose CGI. In literature, Magnetic Resonance (MR) techniques are described by which the flow in the mesenteric vessels is measured pre- and post-prandial in healthy volunteers and CGI patients8-12. The flow in the mesenteric vessels increases post-prandial (hyperemia). However, this increase in post-prandial flow compared to pre-prandial appeared less in CGI patients compared to the healthy volunteers. In some CGI patients, even a decrease of the post-prandial compared to pre-prandial flow was seen. We might be able to distinguish patients with CGI from patients without CGI with MR flow measurements with food stimulation.
Patients undergo verbal counseling and view a photo guide. Patients also complete questionnaires at 2 weeks, 6 and 12 months.
In order to reduce the patient bias, the control eye received a sham laser treatment, under slit lamp, topical anesthesia using 0.5% tetracaine hydrochloride eye drops (Ponti-Ofteno, Laboratorios Sophia, Jalisco, Mexico) and topical 1 mg fluorescein Sodium staining (Bio-Glo, Hub Pharmaceuticals, Rancho Cucamonga CA). Post sham laser care treatment included topical eyedrops of 0.3% tobramycin and 0.1% dexamethasone (Trazidex, Laboratorios Sophia) three times daily, and 0.5 carboxymethylcellulose lubricating eye drops (Refresh-Tears, Allergan, Irving, California, USA). Topical antibiotics and corticosteroids were tapered and discontinued after two weeks.
The invention relates to a Wu houshan bitter tea. The Wu houshan bitter tea comprises the ingredients of polygonum aviculare, andrographis paniculata, radix aucklandiae, fructus aurantii, radix glycyrrhizae and the like. The bitter tea is powder and has a slight bitter taste, and each dose contains 15g of crude drug. The bitter tea has the function of paralyzing nerves so that a nervous system regulates and controls blood vessels, promotes vasoconstriction, slows down blood circulation and reduces body temperature and metabolism is decelerated to speed up dissimilation. The bitter tea mainly treats liver cancer, esophageal cancer, gastric cancer, breast cancer, acute hepatitis, early type 2 diabetes mellitus, aplastic anemia, psychoneurosis, neurodermatitis, sunstroke and the like. The bitter tea has the contradictions that users suffering from phthisis, hepatatrophia, cirrhosis and physical vulnerability and pregnant women are forbidden to take.
Processing of dental moulding compsns., (technical and medical), esp. lining and impression compsns., comprises melting the compsn. and then cooling and retaining at processing temp. Melting is by microwave irradiation. Also claimed is an appts. for carrying out the process. The appts. comprises a chamber (11) carrying a microwave generator (12) by means of which a microwave field is generated in the chamber, and a container (14) insertable in the chamber and contg. the compsn. (17) to be melted.
<P>PROBLEM TO BE SOLVED: To provide a method for inspecting allergic diseases.  <P>SOLUTION: The method for inspecting allergic diseases and a method for screening compounds useful for treating such diseases are provided respectively, with the expression level of an AHR(aryl hydrocarbon receptor, dioxin receptor) gene in a biological specimen as an indicator. Further, a model animal for allergic diseases enhanced in the expression of the AHR gene is also provided. The AHR gene, which is useful as a marker gene for allergic diseases, is such as to be selected as a gene significantly varying in expression in a plurality of bronchoepithelial cells stimulated by IL-4 or IL-13. It has also been confirmed that the expression level of the AHR gene is also enhanced in peripheral blood B cells stimulated by IL4 or IL4+CD40 ligand+anti-IgM antibody.  <P>COPYRIGHT: (C)2004,JPO&NCIPI
The invention relates to a method for the preparation of monomer conjugates of kalicheamycin derivative/carrier of greater loads of the medicament and yield having reduced aggregation. The conjugates are produced by incubation of a kalichemycin derivative and proteinized carrier in a solution containing prorein-compatible non-nuclephilic buffer solution, co-solvent selected from the group consisting of propyleneglycol, ethanol, dimethylsulphoxide and a combination thereof, and an additive including at least one C6-C18 carboxylic acid. The solution has pH from 0.4 to 8.5 and temperature range from 25 to 37°C. The monomer conjugates are isolated for a period of from 15 minutes to 24 hours. Optionally they can be produced by the incubation of a kalicheamycin derivative and a proteinized carrier in a solution containing protein-compatible non-nucleophilic buffer solution and tert.-butanol as co-solvent. 34 claims
The invention provides a ginkgo ketoester tablet. The invention further provides a preparation method and application of the ginkgo ketoester tablet. According to the ginkgo ketoester tablet and the preparation method thereof, provided by the invention, the ginkgo ketoester tablet with high quality can be obtained through the preferable preparation steps and conditions. Compared with the ginkgo ketoester tablets prepared by the conventional method, the ginkgo ketoester tablets have stable quality, low reject ratio and good consistency of different batches of ginkgo ketoester tablets. In particular, the ginkgo ketoester tablet can effectively control ginkgolic acid, and prevent the use of high ginkgolic acid raw materials in the ginkgo ketoester tablet, thereby effectively improving the safety of the ginkgo ketoester tablet. Meanwhile, the ginkgo ketoester tablet prepared by the method has excellent performances such as taste, bitter, stability, high temperature resistance, formability and the like.
PURPOSE: To obtain a safe aq. soln. as a local drug for the treatment for tumor by dissolving a glycerin-1-n-alkyl ether mixture and an alkylphosphocholine in water and adding a buffer to attain to specified pH. CONSTITUTION: The objective soln. of an alkylphosphocholine and glycerin ether which can be used as a local drug for the treatment for tumor is obtd. by adding one or more kinds of alkylphosphocholines (e.g. hexadecylphosphocholine) expressed by formula II to an aq. soln. of a mixture of glycerin-1-n-alkyl ethers comprising DL-glycerin-1-n-ethyl ether, DL-glycerin-1- n-pentyl ether and DL-glycerin-1-n-octyl ether expressed by formula I, and then adding a buffer soln. (e.g. citric acid buffer soln.) to control the pH in 4 to 6. In formula I, R1 , R2 are each a 2 to 12C alkyl or H. In formula II, R is a 12 to 20C alkyl which may have a double or triple bond.
The invention relates to a preparation method of a preparation for treating breast cancer. Breast cancer is a normal malignant tumor, in the recent years, the breast cancer patients become younger and younger, and the reason may relate with the environment and food (pesticide). In the early stage, the breast cancer is hard to detect, and thus the breast cancer harms women's health badly. The provided preparation is developed by combining the traditional Chinese medicine syndrome differentiation principle and modern biological technology. The anticancer active substances are extracted from woodlouse and scorpion, and are capable of inhibiting the growth of cancer cells. Moreover, components having the functions of strengthening body resistance, eliminating evil, resolving stasis, and activating blood are extracted from poria cocos and radix codonopsis. The preparation for treating breast cancer can effectively and radically treat breast cancer and at the same time strengthen the human immunity.
INCRUSE ELLIPTA should not be initiated in patients during rapidly deteriorating or potentially life-threatening episodes of COPD. INCRUSE ELLIPTA has not been studied in subjects with acutely deteriorating COPD. The initiation of INCRUSE ELLIPTA in this setting is not appropriate.

INCRUSE ELLIPTA should not be used for the relief of acute symptoms, i.e., as rescue therapy for the treatment of acute episodes of bronchospasm. INCRUSE ELLIPTA has not been studied in the relief of acute symptoms and extra doses should not be used for that purpose. Acute symptoms should be treated with an inhaled, short-acting beta2-agonist.

If INCRUSE ELLIPTA no longer controls symptoms of bronchoconstriction; the patient’s inhaled, short-acting beta2-agonist becomes less effective; or the patient needs more short-acting beta2-agonist than usual, these may be markers of deterioration of disease. In this setting re-evaluate the patient and the COPD treatment regimen at once. Increasing the daily dose of INCRUSE ELLIPTA beyond the recommended dose is not appropriate in this situation.
Post-Transplant Lymphoproliferative Disorder (PTLD) occurred in patients who received ORENCIA for aGVHD prophylaxis during unrelated HSCT. Of 116 patients who received ORENCIA, 4 patients (3.4%) experienced PTLD. All the PTLD events were associated with Epstein-Barr virus (EBV) infection. Three of the four patients were EBV serology positive at baseline; one patient had negative baseline EBV serology with donor EBV serology unknown. Three of the 4 patients discontinued acyclovir prophylaxis at day 30 post-transplant. The range of time to onset of the events was 49 to 89 days post-transplant. Monitor patients for EBV reactivation in accordance with institutional practices. Provide prophylaxis for EBV infection for 6 months post-transplantation to prevent EBV-associated PTLD [see Dosage and Administration (2.4)].

Cytomegalovirus (CMV) invasive disease occurred in patients who received ORENCIA for aGVHD prophylaxis during unrelated HSCT. Of 116 patients who received ORENCIA, 7% experienced CMV invasive diseases up to day 225 post-transplant. All the patients who experienced CMV invasive disease were CMV serology positive at baseline. The median time to onset of the event was 91 days post-transplant. CMV invasive diseases predominantly involved the gastrointestinal tract [see Adverse Reactions (6.1)].

Monitor patients for CMV infection/reactivation for 6 months post-transplant regardless of the results of donor and recipient pre-transplant CMV serology. Consider prophylaxis for CMV infection/reactivation [see Dosage and Administration (2.4)].
The invention relates to an alizarin vanadium complex, and a preparation method and application thereof, belonging to the field of chemically synthetic drugs. The alizarin vanadium complex is characterized in that the core coordination structural formula of the complex is [VVO2(O2C14H6O2)2(C5N2H12)]-, and the molecular structure is disclosed as Formula I. The anticancer drug effect in-vitro screening experiment proves that the complex has favorable growth inhibition actions on multiple tumor cells and has excellent specificity especially for HCT (colonic adenocarcinoma). The complex has the advantages of high stability, favorable water solubility and favorable fat solubility. Besides, the invention provides a method for preparing the complex. The method has the advantages of accessible raw materials and low cost; the product precipitates in the form of crystals, and has the advantages of high purity and high yield; and thus, the method can satisfy the demands of industrial production. Formula I.
Organ donation after brain death is an alternative to living organ donation, which has various risks and is a means of addressing organ supply shortages. In South Korea, primarily, the organ donation decision is made by the brain-dead donor's family under the guidance of medical staff. Intensive care unit nurses, who are consistently present with patients, can significantly influence families' decision-making process. Hence, nurses' experiences of caring for brain-dead donors should be explored to obtain detailed explanations of the related complex social phenomena. This qualitative study aimed to understand the structure and nature of nurses' experiences using Colaizzi's phenomenological method. Data were collected from 10 intensive care unit nurses from a hospital-based organ procurement organization between June 27 and September 10, 2022. Twelve themes and 5 components were identified from participants' interviews, including "nursing with regret," "enduring agony from repeatedly caring for deceased organ donors," "lack of a support system," "deep emotional pain and scarring left after care," and "balancing emotions." It is necessary to clarify the required nursing interventions and role of nurses in intensive care units who care for brain-dead donors and develop specific guidelines to assist them in their work.
PURPOSE: Provided is a pharmaceutical composition containing an extract of Rhizomes of Nelumbo nucifera Gaertn. which is excellent in liver protecting action and biosafety. Therefore, it is effectively used in the protection of liver cells, the prophylaxis and treatment of liver damage and the inhibition of mutation by a liver carcinogen. CONSTITUTION: The pharmaceutical composition contains, as an active ingredient, a lower alcohol extract of Rhizomes of Nelumbo nucifera Gaertn. which has a consistency. Rhizomes of Nelumbo nucifera Gaertn. is extracted by heating it with 1 to 10 times of lower alcohol, at 60 to 100deg.C for 1 to 12hr. The extract is filtered and concentrated under reduced pressure. The lower alcohol is methanol, an aqueous methanol solution, ethanol, an aqueous ethanol solution, normal propanol, iso-propanol, normal propanol or a mixture thereof. The effective dose of the extract is 1 to 2,000mg/kg body weight/day.
Oxycodone is present in breast milk. Published lactation studies report variable concentrations of oxycodone in breast milk with administration of immediate-release oxycodone to nursing mothers in the early postpartum period. The lactation studies did not assess breastfed infants for potential adverse reactions. Lactation studies have not been conducted with extended–release oxycodone, including oxycodone HCl extended-release tablets, and no information is available on the effects of the drug on the breastfed infant or the effects of the drug on milk production. Because of the potential for serious adverse reactions, including excess sedation and respiratory depression in a breastfed infant, advise patients that breastfeeding is not recommended during treatment with oxycodone HCl extended-release tablets.

Clinical Considerations

Infants exposed to OXYCODONE HCl EXTENDED-RELEASE TABLETS through breast milk should be monitored for excess sedation and respiratory depression. Withdrawal symptoms can occur in breast-fed infants when maternal administration of an opioid analgesic is stopped, or when breast-feeding is stopped.
System configured to detect a carcinogenic lesion located in a portion of human tissue and method. In a first aspect, a system configured to detect a carcinogenic lesion located in a portion of human tissue. The system is characterized by the fact that the system comprises: an image acquisition module, an information extraction module and a cancer discrimination module. The system also comprises a robot arm, where the image acquisition module is coupled to the robot arm, characterized by the robot arm comprises: a distance sensor configured to measure a distance between the distance sensor and a region of The portion of the human tissue and a control module of the robot arm configured to receive the distance measured by the Robot arm distance sensor and reposition the robot arm. A method configured is also described for detecting a cancerous injury located in a portion of human tissue.   (Machine-translation by Google Translate, not legally binding)
Clevidipine was administered in a blinded fashion intravenously, starting with an infusion rate of 0.4 μg/kg/min (non weight-based equivalent is 2 mg/hr), titrating upward, as tolerated by the patient, in doubling increments approximately every 90 seconds up to an infusion rate of 3.2 μg/kg/min (16 mg/hr) to achieve the desired blood pressure-lowering effect. Up-titration to infusion rates above 3.2 μg/kg/min could be used, guided by the patient's response, by increasing the infusion rate in serial increments of 1.5 μg/kg/min, up to the maximum recommended clevidipine infusion rate of 8.0 μg/kg/min. Clevidipine was to be administered for a minimum of 30 minutes, unless bailout occurred, and up to a maximum of one hour.
An apparatus, system or method enables microbubbles to be created on demand for use as the contrast agent within a contrast medium administrable to a patient for purposes of a medical procedure. The system comprises a reservoir, a pressurizing device, a microbubble generator, and a controller. The reservoir stores a liquid. The pressurizing device conveys the liquid, along with the medium formed therewith, through the system. The microbubble generator is used to create the microbubbles within the liquid to form the medium. The microbubble generator has an inlet for receiving the liquid and an outlet for communication of the medium to the patient. The controller controls the operation of the system so that the microbubbles created by the microbubble generator are generated according to the demands of the medical procedure and are administrable within the medium to the patient.
Critically ill patients who experience difficulties in weaning from the ventilator often undergo tracheostomy. These patients usually undergo spontaneous breathing trials receiving oxygen via T-piece. While the high flow oxygen therapy (HFOT) respiratory support system, delivered through nasal cannulas, has demonstrated clinical benefits on respiratory function, limited data exist on whether such effects are also present in HFOT through tracheostomy. Therefore, we plan to perform a study to examine the short-term effects of HFOT on diaphragmatic function in tracheostomized patients with prolonged weaning from mechanical ventilation.

After disconnection from the ventilator, patients will undergo a 30-minute spontaneous breathing trial receiving oxygen either conventionally via T-piece, or by HFOT delivered via tracheostomy, followed by a washout period of 15 min breathing through T-piece and 30 min receiving oxygen with the other modality in a randomized manner. At the start and end of each study period, patients will undergo an assessment through diaphragm ultrasonography, which includes excursion of diaphragmatic dome and thickness of diaphragmatic zone of apposition at end-inspiration and end-expiration. Subsequently, the diaphragmatic thickening fraction will be calculated as the difference between end-inspiratory and end-expiratory thickness divided by end-expiratory thickness. Also. arterial blood gases as well as respiratory rate (RR) and tidal volume (TV) (through a Wright's spirometer) will be measured.